Skip to Content
s - Skip to Content
0 - Access key details
1 - Back to top
2 - Header search

5 Slide Series

Our 5 Slide Series allows us to regularly present objective analyses and trends on issues we believe are of interest and share our findings through data tabulations and visualizations.

This 5 Slide Series edition provides our tabulations and analysis of NCQA’s Quality Ratings for Medicaid MCOs juxtaposed with the specialized accreditations NCQA has awarded to these health plans.

This 5 Slide Series edition provides our tabulations and analysis of the NCQA Quality Ratings for Medicaid MCOs (Rating Year 2022-2023).

This edition provides excerpts of opioid-related questions that have appeared in Medicaid MCO procurements. These slides demonstrate some of the ways in which states are using their request for proposal (RFP) process to promote innovation and elevate the MCOs’ mechanisms to effectively serve enrollees who have opioid use disorder.

This edition looks at various state-level policy changes seeking to restrict inappropriate use of opioids, conducting a pre-versus-post comparison of prescription opioid usage related to the dates of these policy changes.

This edition focuses on the trends in Medicaid prescription opioid and MAT use.  An example of our findings is that opioid prescriptions per Medicaid enrollee decreased 54% from 2013-2022.

This edition quantifies the large gender gaps that exist at the leadership level within U.S. companies. For example, females currently comprise only 10.6% of Fortune 500 Company CEOs. Females are getting closer to parity among attorneys (38%) and physicians (37%), and the trends are all in the direction of parity. However, the gender mix is changing slowly and the disparities remain disturbingly wide.

This edition of our 5 Slide Series quantifies the very low percentage of women serving in national political leadership positions.

This edition summarizes our tabulations of several key Medicaid prescription drug cost and usage trends across the 2018-2022 timeframe. Our findings include:

• Pre-rebate costs per Medicaid prescription grew sharply, at an average annual rate of 9.7% from 2018-2022.
• Prescriptions per Medicaid enrollee have trended steadily downward since the onset of the COVID-19 pandemic.
• Pre-rebate MCO costs per prescription were 38.2% below the corresponding fee-for-service (FFS) figure in 2018 but this differential was less than half as wide (16.6%) during 2022.
• Managed care organizations (MCOs) paid for 74.3% of Medicaid prescriptions during Q4 2021. This proportion dropped to 62.5% in Q4 2022, with the decrease largely attributable to California implementing a carve-out model in January 2022.

This edition conveys some of our perspectives related to the current reinstatement of Medicaid redeterminations. This is an important time period to capture (and share) detailed information on how Medicaid enrollees can best be successfully reached, as well as the dynamics of continuous enrollment, coverage retention and loss. We delineate several specific data points that will be valuable to collect.

This edition focuses on the share of the overall population that receives Medicaid, and how this percentage has trended throughout the past decade nationally and state by state. Between Medicaid expansion, COVID dynamics, and some shifts in the economy’s performance, the past ten years have created several interesting Medicaid enrollment trends and large-scale shifts. Altogether, Medicaid enrollment jumped up 57% from 2013-2022, an increase of 36.2 million persons. Kentucky has experienced the largest rate of growth, ranking 42nd during 2013 in terms of the proportion of its overall population receiving Medicaid coverage and moving all the way to 8th as of 2022.

Back to top